Testing
About 5% of the population has highly elevated Lp(a), a Norwegian review of assessment and treatment in clinical practice (Tidsskr Nor Laegeforen 2023)
Original title: High levels of lipoprotein(a) - assessment and treatment
This review outlines the clinical management of Lp(a) in Norway, noting that approximately 5% of the population has highly elevated, genetically determined Lp(a) levels that raise cardiovascular disease risk. Measuring Lp(a) can improve cardiovascular risk stratification and inform preventive decisions. Current treatment focuses on reducing other modifiable cardiovascular risk factors, since dedicated Lp(a)-lowering drugs remain in clinical trials. The article reviews how Lp(a) should be assessed and managed in everyday clinical practice.
Original abstract
Approximately 5 % of the population have highly elevated levels of lipoprotein(a) (Lp(a)), which is a genetically determined risk factor for cardiovascular disease. Measuring lipoprotein(a) can improve cardiovascular risk stratification and have consequences for preventive measures. Treatment is targeted at reducing modifiable cardiovascular risk factors, but Lp(a)-lowering drugs are being trialled. This article reviews the management of lipoprotein(a) in clinical practice.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.